Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Several current and former FDA employees who spoke to Inside Medicine on the condition of anonymity have come to see the ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Novavax announces significantly improved terms for collaboration and license pact with Takeda for Nuvaxovid in Japan: Gaithersburg, Maryland Tuesday, May 6, 2025, 14:00 Hrs [IST] ...

Dr. Vinay Prasad succeeds Dr. Peter Marks, who left the role of leader of the FDA’s Center for Biologics Evaluation and ...

A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

The U.S. FDA has appointed Vinay Prasad to be the next director of its Center for Biologics Evaluation and Research division ...